Business Context and Reporting Period
Company: ProMIS Neurosciences Inc. (PMN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative diseases, specifically targeting toxic misfolded proteins. The company utilizes its proprietary EpiSelect™ computational platform to identify disease-specific epitopes. Key product candidates include PMN310 (Alzheimer's disease), PMN267 (ALS), and PMN442 (synucleinopathies). The company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(39.7) million | $2.8 million (Net Income) |
| Operating Expenses | $40.2 million | $16.8 million |
| Research & Development (R&D) | $33.4 million | $10.6 million |
| General & Administrative (G&A) | $6.8 million | $6.2 million |
| Cash Flow from Operations | $(28.1) million | $(27.2) million |
| Cash and Short-term Investments (End of Period) | $6.1 million | $13.3 million |
| Accumulated Deficit | $(130.4) million | $(90.7) million |
| Working Capital | $(1.2) million | $16.7 million |
Note: 2024 Net Income was driven by a $22.6 million non-cash gain on the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Operating Loss Expansion: The company shifted from a net income of $2.8 million in 2024 to a net loss of $39.7 million in 2025. This reversal is primarily due to the absence of the $22.6 million non-cash gain on warrant liability revaluation recorded in 2024 and a significant increase in R&D spending.
- R&D Expense Surge: R&D expenses increased by $22.7 million (214%) year-over-year, driven by the progression of the PMN310 Phase 1b clinical trial (PRECISE-AD), which began in late 2024.
- Liquidity Position: Cash and short-term investments decreased by approximately $7.2 million during 2025 due to operating cash burn, despite financing activities providing $20.9 million in cash inflows.
- Capital Structure: The company executed a 25:1 reverse share split in November 2025. All share and per-share data in this report have been retroactively adjusted.
Guidance, Outlook, and Risks
Clinical Outlook and Milestones
- PMN310 (Alzheimer's): The Phase 1b PRECISE-AD trial enrollment was completed in December 2025 with 144 subjects. The company expects to complete six-month assessments in Q2 2026, with blinded interim analysis anticipated in early Q3 2026. Top-line data is expected in early 2027.
- PMN267 (ALS) & PMN442 (Synucleinopathies): These candidates remain in preclinical development stages.
Liquidity and Capital Resources
- Subsequent Financing: In January 2026, the company completed a private placement raising gross proceeds of $75.5 million. Management expects existing cash, including these proceeds, to fund operations through 2027.
- Future Needs: The company anticipates continued losses and will require additional financing for future clinical activities and commercialization efforts.
Key Risks
- Development Risk: Product candidates are in early stages; clinical trials may fail to demonstrate safety or efficacy. The Alzheimer's field has historically seen limited success.
- Financial Risk: The company has an accumulated deficit of $130.4 million and negative working capital as of year-end 2025. Failure to secure additional capital could force delays or termination of programs.
- Regulatory Risk: Approval is not guaranteed. Changes in FDA policies or government shutdowns could delay reviews.
- Intellectual Property: Reliance on licensed technology from the University of British Columbia (UBC); potential challenges to patent validity.
Investor Verification Checklist
- Cash Runway: Verify the actual cash balance post-January 2026 financing and confirm the burn rate against the "through 2027" guidance.
- PMN310 Trial Status: Monitor the Q2/Q3 2026 interim data release for safety (specifically ARIA events) and biomarker efficacy signals.
- Dilution Impact: Review the terms of the January 2026 private placement (warrants, pre-funded warrants) to assess potential future dilution upon exercise.
- Warrant Liability Accounting: Confirm that the significant non-cash gain in 2024 does not recur, as future warrant valuations may result in losses rather than gains.
- Reverse Split Compliance: Ensure all historical share counts and per-share metrics are correctly adjusted for the 25:1 reverse split effective November 2025.